Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.03 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $13.25 million versus the consensus estimate of $16.13 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.